Skip to main content
Top
Published in: Tumor Biology 4/2010

01-08-2010 | Research Article

WWOX gene may contribute to progression of non-small-cell lung cancer (NSCLC)

Authors: Onur Baykara, Ahmet Demirkaya, Kamil Kaynak, Serhan Tanju, Alper Toker, Nur Buyru

Published in: Tumor Biology | Issue 4/2010

Login to get access

Abstract

Lung cancer is the most common cause of cancer-related death worldwide and, like many other cancers, is affected by different genetic, epigenetic, and environmental factors. The WW domain-containing oxidoreductase (WWOX) gene is a tumor-suppressor gene located on chromosome 16q23.3–24.1, and it has been shown that it loses its function due to alterations in genetic and epigenetic mechanisms. The aim of this study is to investigate the relationship between lung cancer and WWOX gene. Tumor tissue samples, corresponding normal tissues, and blood samples obtained from 50 lung cancer patients were involved in the study. We analyzed methylation profile by methylation-specific PCR and mutations and polymorphisms by DNA sequencing. Methylation analysis showed that promoter hypermethylation was present in 38 of 50 (76%) patients. In addition, promoter region of WWOX gene of younger patients was more frequently methylated than older patients. Using DNA sequencing, we found four genetic alterations in WWOX gene. Two of them were germline mutations (Exon 4 and 7), and two of them were polymorphic (Exon 6 and 8). We found a new mutation in exon 7 (Arg-254→Cys) which has not been described previously. The changes in the short-chain dehydrogenase domain of the protein caused by the genetic alterations may affect the function of the gene. We conclude that hypermethylation of WWOX gene promoter region and mutations in the gene might be related to lung carcinogenesis.
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisami P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisami P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
2.
go back to reference La Vecchia C, Franceschi S, Levi F. Epidemiological research on cancer with a focus on Europe. Eur J Cancer Prev. 2003;12:5–14.CrossRefPubMed La Vecchia C, Franceschi S, Levi F. Epidemiological research on cancer with a focus on Europe. Eur J Cancer Prev. 2003;12:5–14.CrossRefPubMed
3.
go back to reference Peto R, Darby S, Deo H. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321:323–9.CrossRefPubMed Peto R, Darby S, Deo H. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321:323–9.CrossRefPubMed
4.
go back to reference Simonato L, Agudo A, Ahrens W. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogenity. Int J Cancer. 2001;91:876–87.CrossRefPubMed Simonato L, Agudo A, Ahrens W. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogenity. Int J Cancer. 2001;91:876–87.CrossRefPubMed
5.
go back to reference Capewell S, Sankaran R, Lamb D. Lung cancer in lifelong non-smokers. Edinburgh Lung Cancer Group. Thorax. 1991;46:565–8.CrossRefPubMed Capewell S, Sankaran R, Lamb D. Lung cancer in lifelong non-smokers. Edinburgh Lung Cancer Group. Thorax. 1991;46:565–8.CrossRefPubMed
6.
go back to reference Yunis JJ, Sarens AL, Bowe AE. Fragile sites are targets of diverse mutagens and carcinogens. Oncogene. 1987;1:59–69.PubMed Yunis JJ, Sarens AL, Bowe AE. Fragile sites are targets of diverse mutagens and carcinogens. Oncogene. 1987;1:59–69.PubMed
7.
go back to reference Bednarek AK, Laflin KJ, Daniel RL, et al. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3–24.1, a region frequently affected in breast cancer. Cancer Res. 2000;60:2140–5.PubMed Bednarek AK, Laflin KJ, Daniel RL, et al. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3–24.1, a region frequently affected in breast cancer. Cancer Res. 2000;60:2140–5.PubMed
8.
go back to reference Ludes-Meyers JH, Bednarek AK, Popescu NC, et al. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res. 2003;100:101–10.CrossRefPubMed Ludes-Meyers JH, Bednarek AK, Popescu NC, et al. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res. 2003;100:101–10.CrossRefPubMed
9.
go back to reference Ludes-Meyers JH, Kil H, Bednarek AK, et al. WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene. 2004;23:5049–55.CrossRefPubMed Ludes-Meyers JH, Kil H, Bednarek AK, et al. WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene. 2004;23:5049–55.CrossRefPubMed
10.
go back to reference Aqeilan RI, Pekarsky Y, Herrero JJ, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci. 2004;101:4401–6.CrossRefPubMed Aqeilan RI, Pekarsky Y, Herrero JJ, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci. 2004;101:4401–6.CrossRefPubMed
11.
go back to reference Aqeilan RI, Palamarchuk A, Weigel RJ, et al. Physical and functional interactions between the WWOX tumor suppressor protein and the AP-2λ transcription factor. Cancer Res. 2004;64:8256–61.CrossRefPubMed Aqeilan RI, Palamarchuk A, Weigel RJ, et al. Physical and functional interactions between the WWOX tumor suppressor protein and the AP-2λ transcription factor. Cancer Res. 2004;64:8256–61.CrossRefPubMed
12.
go back to reference Aqeilan RI, Donati V, Palamarchuk A, et al. WW-domain containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res. 2005;65:6764–72.CrossRefPubMed Aqeilan RI, Donati V, Palamarchuk A, et al. WW-domain containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res. 2005;65:6764–72.CrossRefPubMed
13.
go back to reference Hezova R, Ehrmann J, Kolar Z. WWOX, a new potential tumor supressor gene. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151(1):11–5.PubMed Hezova R, Ehrmann J, Kolar Z. WWOX, a new potential tumor supressor gene. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007;151(1):11–5.PubMed
14.
go back to reference Chang N-S, Doherty J, Ensign A. JNK1 physically interacts with WW-domain containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem. 2003;278:9195–202.CrossRefPubMed Chang N-S, Doherty J, Ensign A. JNK1 physically interacts with WW-domain containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem. 2003;278:9195–202.CrossRefPubMed
15.
go back to reference Wang X, Chao L, Jin G, et al. Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumor Biol. 2009;30:8–14.CrossRef Wang X, Chao L, Jin G, et al. Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumor Biol. 2009;30:8–14.CrossRef
16.
go back to reference Alsop AE, Taylor K, Zhang J, et al. Homozygous deletions may be markers of nearby heterozygous mutations.: the complex deletion at FRA16D in the colon cancer cell line removes exons of WWOX genes. Chromosomes & cancer. 2008;47:437–47.CrossRef Alsop AE, Taylor K, Zhang J, et al. Homozygous deletions may be markers of nearby heterozygous mutations.: the complex deletion at FRA16D in the colon cancer cell line removes exons of WWOX genes. Chromosomes & cancer. 2008;47:437–47.CrossRef
17.
go back to reference Aqeilan RI, Trapasso F, Hussain S, et al. Targeted deletions of WWOX reveals a tumor suppressor function. Proc Nat Acad Sci. 2007;104:3949–54.CrossRefPubMed Aqeilan RI, Trapasso F, Hussain S, et al. Targeted deletions of WWOX reveals a tumor suppressor function. Proc Nat Acad Sci. 2007;104:3949–54.CrossRefPubMed
18.
go back to reference Wang M, Gu J, Wang Y, et al. Loss of WWOX expression in human extrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol. 2008;135(1):39–44.CrossRefPubMed Wang M, Gu J, Wang Y, et al. Loss of WWOX expression in human extrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol. 2008;135(1):39–44.CrossRefPubMed
19.
go back to reference Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 2002;62:2258–60.PubMed Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 2002;62:2258–60.PubMed
20.
go back to reference Herman JG, Graff JR, Myöhanen S, et al. Methylation-specific PCR: a novel PCR assay for metylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.CrossRefPubMed Herman JG, Graff JR, Myöhanen S, et al. Methylation-specific PCR: a novel PCR assay for metylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.CrossRefPubMed
21.
go back to reference Yendamuri S, Kuroki T, Trapasso F, et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res. 2003;63:878–81.PubMed Yendamuri S, Kuroki T, Trapasso F, et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res. 2003;63:878–81.PubMed
22.
go back to reference Donati V, Fontanini G, Dell’Omodarme M, et al. WWOX expression in different histological types and subtypes of non-small cell lung cancer. Clin Cancer Res. 2007;13:884–91.CrossRefPubMed Donati V, Fontanini G, Dell’Omodarme M, et al. WWOX expression in different histological types and subtypes of non-small cell lung cancer. Clin Cancer Res. 2007;13:884–91.CrossRefPubMed
23.
go back to reference Paige AJ, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA. 2001;98:11417–22.CrossRefPubMed Paige AJ, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA. 2001;98:11417–22.CrossRefPubMed
24.
go back to reference Pimenta F, Gomes DA, Perdigao PF, et al. Characterization of the tumor supressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer. 2006;118:1154–8.CrossRefPubMed Pimenta F, Gomes DA, Perdigao PF, et al. Characterization of the tumor supressor gene WWOX in primary human oral squamous cell carcinomas. Int J Cancer. 2006;118:1154–8.CrossRefPubMed
25.
go back to reference Kuroki T, Yendamuri S, Trapasso F, et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res. 2004;10:2459–65.CrossRefPubMed Kuroki T, Yendamuri S, Trapasso F, et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res. 2004;10:2459–65.CrossRefPubMed
26.
go back to reference Iliopoulos D, Guler G, Han SY, et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene. 2005;24:1625–33.CrossRefPubMed Iliopoulos D, Guler G, Han SY, et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene. 2005;24:1625–33.CrossRefPubMed
Metadata
Title
WWOX gene may contribute to progression of non-small-cell lung cancer (NSCLC)
Authors
Onur Baykara
Ahmet Demirkaya
Kamil Kaynak
Serhan Tanju
Alper Toker
Nur Buyru
Publication date
01-08-2010
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0039-3

Other articles of this Issue 4/2010

Tumor Biology 4/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine